Top

Pediatric Nephrology

Published in:

01-08-2013 | Original Paper

Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5

Authors: Pornpimol Rianthavorn, Pantipa Boonyapapong

Published in: Pediatric Nephrology | Issue 8/2013

Abstract

Background

Vitamin D insufficiency is related to erythropoietin resistance in chronic kidney disease (CKD). This study was conducted to evaluate the effect of ergocalciferol on the dose of erythrocyte-stimulating agent (ESA) administered to children with CKD stage 5 and vitamin D insufficiency.

Methods

Twenty patients aged <18 years with CKD stages 5 or 5D and vitamin D insufficiency were divided into two groups. During the 12-week study, ten patients received oral ergocalciferol (treatment) whereas the other ten patients did not (control). The ESA dosage was recorded monthly.

Results

There were no significant differences in demographic data, ESA dosages, and laboratory data, including corrected calcium, phosphorus, parathyroid hormone, hemoglobin, ferritin, 25-hydroxyvitamin D (25D), and transferrin saturation levels, between the two groups at baseline. At the completion of the study, serum 25D levels in the treatment group were significantly increased from baseline (p = 0.02) and were significantly higher than the serum 25D levels in the controls (p < 0.005). The ESA dosage in the treatment group was significantly decreased when compared to baseline (p = 0.04).

Conclusions

Vitamin D deficiency should be routinely detected and treated. Our results show that the administration of ergocalciferol in conjunction with 1,25-dihydroxyvitamin D3 reduced the dose of ESA required to treat children with CKD stages 5 and 5D and may decrease erythropoietin resistance.

Heaf JG, Joffe P, Marckmann P (2012) Vitamin d and stage 5 chronic kidney disease: A new paradigm? Semin Dial 25:50–58CrossRefPubMed

Hollis BW (2005) Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135:317–322PubMed

Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW (2007) Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 105:c132–138PubMed

Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004–1013CrossRefPubMed

Wang AY, Lam CW, Sanderson JE, Wang M, Chan IH, Lui SF, Sea MM, Woo J (2008) Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: A 3-y prospective cohort study. Am J Clin Nutr 87:1631–1638PubMed

National Kidney Foundation (2005) K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46:S48–52

KDIGO (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113:S1–130

Alon DB, Chaimovitz C, Dvilansky A, Lugassy G, Douvdevani A, Shany S, Nathan I (2002) Novel role of 1,25(OH)(2)D(3) in induction of erythroid progenitor cell proliferation. Exp Hematol 30:403–409CrossRefPubMed

Sim JJ, Lac PT, Liu IL, Meguerditchian SO, Kumar VA, Kujubu DA, Rasgon SA (2010) Vitamin D deficiency and anemia: A cross-sectional study. Ann Hematol 89:447–452CrossRefPubMed

10.

Kendrick J, Targher G, Smits G, Chonchol M (2009) 25-Hydroxyvitamin D deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease. Am J Nephrol 30:64–72CrossRefPubMed

11.

Patel NM, Gutierrez OM, Andress DL, Coyne DW, Levin A, Wolf M (2010) Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int 77:715–720CrossRefPubMed

12.

Kiss Z, Ambrus C, Almasi C, Berta K, Deak G, Horonyi P, Kiss I, Lakatos P, Marton A, Molnar MZ, Nemeth Z, Szabo A, Mucsi I (2011) Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis. Nephron Clin Pract 117:c373–378CrossRefPubMed

13.

Armas LA, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89:5387–5391CrossRefPubMed

14.

National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1–201

15.

Kumar VA, Kujubu DA, Sim JJ, Rasgon SA, Yang PS (2011) Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. J Nephrol 24:98–105CrossRefPubMed

16.

National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39:S1–266CrossRef

17.

Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34:571–590PubMed

18.

National Kidney Foundation (2006) KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47:S11–145CrossRef

19.

Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, Jaccard N, Knoll E, Stern N (2005) 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111:1666–1671CrossRefPubMed

20.

Segersten U, Holm PK, Bjorklund P, Hessman O, Nordgren H, Binderup L, Akerstrom G, Hellman P, Westin G (2005) 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue. Breast Cancer Res 7:R980–986CrossRefPubMed

21.

Blazsek I, Farabos C, Quittet P, Labat ML, Bringuier AF, Triana BK, Machover D, Reynes M, Misset JL (1996) Bone marrow stromal cell defects and 1 alpha,25-dihydroxyvitamin D3 deficiency underlying human myeloid leukemias. Cancer Detect Prev 20:31–42PubMed

22.

Dusso A, Brown A, Slatopolsky E (1994) Extrarenal production of calcitriol. Semin Nephrol 14:144–155PubMed

23.

Barany P, Divino Filho JC, Bergstrom J (1997) High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29:565–568CrossRefPubMed

24.

Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281CrossRefPubMed

25.

Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83:754–759PubMed

26.

Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreno V, Caramelo C (1998) Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 54:1337–1343CrossRefPubMed

27.

Coen G, Taccone Gallucci M, Bonucci E, Ballanti P, Bianchi AR, Bianchini G, Matteucci MC, Mazzaferro S, Picca S, Taggi F, Cinotti GA, Casciani CU (1983) 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: Comparison of combined versus 1,25(OH)2D3 administration alone. Miner Electrolyte Metab 9:19–27PubMed

28.

Brancaccio D, Cozzolino M, Gallieni M (2004) Hyperparathyroidism and anemia in uremic subjects: A combined therapeutic approach. J Am Soc Nephrol 15[Suppl]:S21–24CrossRefPubMed

29.

Rao DS, Shih MS, Mohini R (1993) Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328:171–175CrossRefPubMed

30.

Seeherunvong W, Abitbol CL, Chandar J, Zilleruelo G, Freundlich M (2009) Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J Pediatr 154:906–911CrossRefPubMed

31.

Belostotsky V, Mughal Z, Webb NJ (2009) A single high dose of ergocalciferol can be used to boost 25-hydroxyvitamin D levels in children with kidney disease. Pediatr Nephrol 24:625–626CrossRefPubMed

32.

Menon S, Valentini RP, Hidalgo G, Peschansky L, Mattoo TK (2008) Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol 23:1831–1836CrossRefPubMed

33.

Rianthavorn P, Ettenger RB, Salusky IB, Kuizon BD (2010) Trabecular bone volume and osteoprotegerin expression in uremic rats given high calcium. Pediatr Nephrol 25:2311–2319CrossRefPubMed

34.

Fishbane S, Besarab A (2007) Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2:1274–1282CrossRefPubMed

Title: Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5
Authors: Pornpimol Rianthavorn
Pantipa Boonyapapong
Publication date: 01-08-2013
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 8/2013
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-013-2431-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2013

The renal biopsy in the genomic era

Over- or underfill: not all nephrotic states are created equal

Author Index for the Abstracts for the IPNA Congress, 30 August - 3 September 2013, Shanghai, China

Preoperative prediction of acute kidney injury—from clinical scores to biomarkers

Cell polarity and cystic kidney disease

Long-term neurocognitive outcomes of patients with end-stage renal disease during infancy